Filtered By:
Nutrition: Omega 3
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 227 results found since Jan 2013.
The effect of omega-3 polyunsaturated fatty acids on stroke treatment and prevention: a systematic review and meta-analysis
Conclusion: this systematic review and meta-analysis suggests that treatment with low-dose n-3 PUFAs can reduce cerebrovascular disease-related death. After the oral administration of n-3 PUFAs, the levels of TC and TG decreased significantly, but n-3 PUFAs did not prevent the occurrence of cerebrovascular accidents or improve LDL or HDL levels.PMID:35916137 | DOI:10.20960/nh.04148
Source: Nutricion Hospitalaria - August 2, 2022 Category: Nutrition Authors: Qian Xu Lingling Du Heng Gu Meng Ji Ling Zhan Source Type: research
Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
CONCLUSIONS: Our analyses demonstrate that although EPA supplementation lowers risk of coronary revascularization more than other oils, there may not be a benefit relative to standard of care. Further, EPA reduces the risk of cardiovascular events only in comparison to mineral oil and not when compared with other placebo oils or controls. In contrast, combined EPA+DHA was associated with reduced risk of cardiovascular death compared to controls.PMID:35914996 | DOI:10.1016/j.jjcc.2022.07.008
Source: Journal of Cardiology - August 1, 2022 Category: Cardiology Authors: Yujiro Yokoyama Toshiki Kuno Sae X Morita Leandro Slipczuk Hisato Takagi Alexandros Briasoulis Azeem Latib Sripal Bangalore Sean P Heffron Source Type: research
Effects of omega-3 fatty acid on major cardiovascular outcomes: A systematic review and meta-analysis
Conclusions:
Major cardiovascular events and cardiac death risks could be avoided with the use of omega-3 fatty acid. However, it has no significant effects on the risk of all-cause mortality, myocardial infarction, and stroke.
Source: Medicine - July 29, 2022 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality
CONCLUSIONS: Higher concentrations of marine-derived omega-3 PUFA biomarkers were associated with a significantly reduced risk of total CVD, CHD, and total mortality. Levels of ALA were inversely associated with a lower risk of T2D but not CVD-related outcomes. These data support the dietary recommendations advocating the role of omega-3 PUFAs in maintaining an overall lower risk of developing cardiovascular disease and premature deaths.PMID:35830775 | DOI:10.1016/j.clnu.2022.06.034
Source: Clinical Colorectal Cancer - July 13, 2022 Category: Cancer & Oncology Authors: Hong Jiang Lina Wang Duolao Wang Ni Yan Chao Li Min Wu Fan Wang Baibing Mi Fangyao Chen Wanru Jia Xi Liu Jiaxin Lv Yan Liu Jing Lin Le Ma Source Type: research
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
ConclusionsIcosapent ethyl is cost effective for primary and secondary cardiovascular prevention at an annual price of £2064 in the UK. For PCSK9 inhibitors, price discounts or prescription restrictions are necessary to achieve cost effectiveness.Graphical abstract
Source: Clinical Drug Investigation - July 11, 2022 Category: Drugs & Pharmacology Source Type: research
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey)
CONCLUSIONS: Among patients receiving statins, cardiovascular event incidence did not differ significantly between O3AEE-treated patients and non-O3AEE-treated patients. Further studies are required before definitive conclusions can be drawn on the effect of O3AEE on cardiovascular event incidence in high-risk patients with hypertriglyceridemia.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02285166.PMID:35772177 | DOI:10.1080/14740338.2022.2094914
Source: Expert Opinion on Drug Safety - June 30, 2022 Category: Drugs & Pharmacology Authors: Tamio Teramoto Hisao Ogawa Hirotsugu Ueshima Yasushi Okada Kazuo Haze Shigeyuki Matsui Keita Fujikawa Takamasa Hashimoto Sho Sakui Kunihiko Nishimura Mika Kajita Atsushi Horimoto Jovelle Fernandez Source Type: research
